Ebonyi State has launched Nigeria’s first program to distribute lenacapavir, a long acting injectable HIV prevention drug, marking a major advance in the country’s fight against the virus. The state’s health ministry announced the initiative on Monday, making it the first sub Saharan African region to offer the twice yearly injection as part of routine HIV prevention services.
Eight public health facilities across Ebonyi, including the Alex Ekwueme Federal Teaching Hospital Abakaliki, will provide lenacapavir to eligible residents. The rollout follows regulatory approvals from the U.S. Food and Drug Administration and the European Medicines Agency, which validated the drug’s safety and effectiveness based on clinical trial data.
What Happened
The Ebonyi State Ministry of Health confirmed the launch of lenacapavir as a preventive treatment for HIV, administered as a subcutaneous injection every six months. The program targets individuals at elevated risk of infection, including sex workers, men who have sex with men, and serodiscordant couples. Health officials stated that training for healthcare providers began last month, with the first doses administered this week.
Why Public Health Officials Are Concerned
Despite progress in HIV treatment, Nigeria remains one of the countries with the highest HIV burdens globally, with an estimated 1.9 million people living with the virus, according to the World Health Organization. Traditional daily oral pre exposure prophylaxis (PrEP) has faced challenges in adherence, particularly among key populations. Lenacapavir’s twice yearly dosing offers a practical solution to improve prevention coverage and reduce new infections.
Public health experts note that Ebonyi’s initiative could serve as a model for other Nigerian states and neighboring countries. The state government has pledged to monitor uptake, side effects, and long term outcomes to inform future scale up efforts.
Symptoms or Risk Factors
HIV transmission occurs through unprotected sexual contact, sharing of needles, and from mother to child during pregnancy, childbirth, or breastfeeding. While the virus itself does not cause immediate symptoms, early infection may present with flu like symptoms such as fever, fatigue, and sore throat. Without treatment, HIV can progress to AIDS, severely weakening the immune system.
Groups at higher risk include:
- Sex workers
- Men who have sex with men
- People with multiple sexual partners
- Individuals with a sexual partner known to be HIV positive
- People who inject drugs
Who May Be Affected
The lenacapavir program prioritizes individuals in Ebonyi State who are at substantial risk of HIV exposure. Eligibility will be determined through clinical assessment at designated facilities. Health authorities have emphasized that the drug is not a cure and does not replace safer sex practices or regular HIV testing.
Community health workers will conduct outreach to raise awareness and facilitate access, particularly in urban centers and high risk communities. The state has also committed to ensuring equitable distribution across rural areas.
Government or WHO Response
The Nigerian Federal Ministry of Health has expressed support for Ebonyi’s initiative, calling it a critical step toward achieving national HIV prevention targets. The ministry is collaborating with partners including the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria to expand access to lenacapavir nationwide.
The World Health Organization has included long acting injectable PrEP, including lenacapavir, in its guidelines for HIV prevention, citing evidence of high efficacy and improved adherence. The organization continues to monitor global rollouts and provide technical assistance to countries adopting the intervention.
Prevention and Safety Guidance
Lenacapavir is intended for individuals who are HIV negative and at ongoing risk of infection. It should be used in combination with other prevention strategies, such as consistent condom use, regular HIV testing, and antiretroviral therapy for HIV positive partners in serodiscordant relationships.
Healthcare providers will screen recipients for HIV and other sexually transmitted infections before administration. The injection is administered by a trained professional and has been associated with mild to moderate side effects in clinical trials, including injection site reactions and headache. Routine follow up visits are required to monitor safety and effectiveness.
Public health officials urge residents to continue practicing safe behaviors and to seek HIV testing every three to six months, regardless of whether they are using lenacapavir.
What Readers Should Know
This is the first public health program in sub Saharan Africa to offer lenacapavir as part of routine HIV prevention services. While the drug represents a significant advance, access remains limited to designated facilities in Ebonyi State for now. Nationwide expansion will depend on funding, supply chain readiness, and sustained government commitment.
For individuals considering lenacapavir, consultation with a healthcare provider is essential to assess eligibility and discuss risks and benefits. The drug does not protect against other sexually transmitted infections and should be used alongside comprehensive prevention strategies.
Key Takeaways
- Ebonyi State is the first in Nigeria and sub Saharan Africa to offer lenacapavir, a twice yearly injectable HIV prevention drug.
- The program targets high risk groups, including sex workers, men who have sex with men, and serodiscordant couples.
- Lenacapavir addresses adherence challenges linked to daily oral PrEP, potentially improving prevention coverage.
- The initiative aligns with WHO guidelines and may serve as a model for national scale up with support from PEPFAR and the Global Fund.
- Access remains limited to eight designated facilities in Ebonyi State; nationwide rollout depends on funding and logistics.
Frequently Asked Questions
What is lenacapavir and how does it work?
Lenacapavir is a long acting injectable antiretroviral medication developed by Gilead Sciences. It works by blocking HIV from entering and replicating in cells. Administered as a subcutaneous injection every six months, it provides sustained protection against HIV infection when used as prescribed.
Who is eligible to receive lenacapavir in Ebonyi State?
Eligibility is determined by healthcare providers at designated facilities. Priority is given to individuals at high risk of HIV infection, including sex workers, men who have sex with men, and people in serodiscordant relationships. A clinical assessment will confirm HIV negative status before administration.
How effective is lenacapavir compared to daily oral PrEP?
Clinical trials have shown lenacapavir to be highly effective in preventing HIV when taken as prescribed. Its long acting formulation addresses adherence challenges associated with daily oral PrEP, potentially improving real world effectiveness in high risk populations.
Are there side effects associated with lenacapavir?
In clinical trials, common side effects included injection site reactions and headache. Serious side effects are rare. Recipients will be monitored during follow up visits to assess safety and tolerability.
Will lenacapavir be available in other Nigerian states soon?
The Ebonyi State program is a pilot initiative. Expansion to other states will depend on funding, supply chain readiness, and government approval. Federal health authorities and international partners are actively exploring options for nationwide scale up.
Medical Review: MedSense Editorial Board
DISCUSSION (0)
POST A COMMENT